{
    "nctId": "NCT03109249",
    "briefTitle": "Pharmacokinetic Study of SPARC1613 and reference1613 in Subjects With Locally Recurrent or Metastatic Breast Cancer",
    "officialTitle": "Pharmacokinetic Study of SPARC1613 and reference1613 in Subjects With Locally Recurrent or Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Recurrent or Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 142,
    "primaryOutcomeMeasure": "Maximum observed concentration (Cmax)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* The subject has given written, informed consent and is available for the duration of study\n* Histologically or cytologically confirmed diagnosis of breast cancer\n* Male or female aged \u2265 18 years\n* Females subjects of child-bearing potential must have a negative urine pregnancy test\n* Female subjects must be non-lactating and non-breastfeeding\n* Subject must be willing and able to comply with scheduled visits, treatment plan and laboratory testing\n\nExclusion Criteria:\n\n* Known hypersensitivity to either of the study drugs or their excipients\n* Inability to undergo venipuncture and/or tolerate venous access\n* Pre-existing clinically significant peripheral neuropathy\n* Positive laboratory exclusion test (HIV, HBsAg, or HCV)\n* Treatment with investigational agents or participation in clinical trial within 30 days of study entry",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}